Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang C
- DOI
- 10.1056/NEJMoa2301425
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/4e89a70c-9ece-43f0-ac90-37dc0269acbb is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ReportingData & code availability partially met−0.25★
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and well-reported phase 2-3 randomized controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weakness is the vague data sharing statement, which lacks concrete access details. Minor copyedit issues (e.g., subject-verb agreement) do not affect scientific integrity.
Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed only 1 test; other statistics were not machine-verified but no errors were flagged.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.
- CONSISTENTreported p = .006 · recomputed p = .006Reviewers 1, 2Primary endpoint p-value from Peto-Prentice test
“P=0.006 by Peto–Prentice test”
Taken as given: The Peto-Prentice test statistic is approximately normal.; The reported p-value is two-sided.Method: Approximated using normal distribution with z=2.75, which yields p≈0.006.How we recomputed it: pZ(2.75)
- lowinternal contradictionThe abstract states 1208 patients were enrolled, but the full analysis population is 1139. This is explained by the exclusion of patients who did not receive the first dose, so it is not a contradiction.
A total of 1208 patients were enrolled at 35 sites in China; 603 were assigned to receive simnotrelvir and 605 to receive placebo. After randomization, 1139 patients received trial drug or placebo and were included in the full analysis population.
Abstractreviewer’s wording
Overstated conclusions
None foundConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
Checked — nothing surfaced.
5 major claims checked against the paper's own evidence: all adequately supported.
- supportedReviewers 1, 2Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19.The primary endpoint was met with a statistically significant difference in time to sustained resolution.Evidence: Primary endpoint result: median time 180.1 vs 216.0 hours, P=0.006.
“Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns.”
ConclusionFind in source - supportedReviewers 1, 2Simnotrelvir plus ritonavir reduced viral load compared to placebo.Viral load reduction was significantly greater in the simnotrelvir group on day 5.Evidence: Day 5 viral load difference: -1.51 log10 copies/mL (95% CI -1.79 to -1.24).
“On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group than in the placebo group (mean difference [±SE], −1.51±0.14 log 10 copies per milliliter; 95% CI, −1.79 to −1.24).”
AbstractFind in source - supportedReviewer 1Simnotrelvir plus ritonavir was safe with no evident safety concerns.Adverse events were more frequent but mostly mild or moderate, with no serious events in the simnotrelvir group.Evidence: Adverse events 29.0% vs 21.6%; no serious adverse events in simnotrelvir group.
“The incidence of adverse events during treatment was higher in the simnotrelvir group than in the placebo group (29.0% vs. 21.6%). Most adverse events were mild or moderate.”
AbstractFind in source - supportedReviewer 2The incidence of adverse events was higher in the simnotrelvir group than in the placebo group.The safety data show a higher incidence of adverse events in the simnotrelvir group.Evidence: Adverse events: 29.0% vs 21.6%.
“The incidence of adverse events during treatment was higher in the simnotrelvir group than in the placebo group (29.0% vs. 21.6%).”
AbstractFind in source - supportedReviewer 2Simnotrelvir had more benefits for the alleviation of respiratory symptoms than placebo.The post hoc analysis showed a significant difference in time to resolution of respiratory symptoms.Evidence: Median between-group difference, −41.4 hours; 95% CI, −70.7 to −13.3.
“Simnotrelvir had more benefits for the alleviation of respiratory symptoms than placebo.”
Discussion ¶1Find in source
Efficacy claim is anchored to an adequate endpoint and a meaningful effect.
- ADEQUATESurrogate endpointThe primary endpoint is time to sustained resolution of symptoms, a patient-reported clinical outcome, not a surrogate biomarker. Although viral load is a secondary endpoint, the primary claim is based on symptom resolution, which is a direct clinical measure.
“The primary efficacy end point was the time to sustained resolution of symptoms, defined as the absence of 11 Covid-19–related symptoms for 2 consecutive days.”
- ADEQUATEEffect sizeThe primary effect is a median difference of -35.8 hours (about 1.5 days) in time to symptom resolution, which is statistically significant and clinically meaningful as it represents a meaningful shortening of illness duration. The effect is anchored to a clinical outcome (symptom resolution) and is supported by a prespecified endpoint.
“the time to sustained resolution of Covid-19 symptoms was significantly shorter in the simnotrelvir group than in the placebo group (180.1 hours [95% confidence interval {CI}, 162.1 to 201.6] vs. 216.0 hours [95% CI, 203.4 to 228.1]; median difference, −35.8 hours [95% CI, −60.1 to −12.4]; P=0.006 by Peto–Prentice test).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites prior research on other 3CLpro inhibitors (nirmatrelvir, ensitrelvir) and simnotrelvir's in vitro activity and phase 1B results, establishing the rationale for the trial. The premise is logically connected to the study objective of evaluating simnotrelvir's efficacy and safety. Limitations of prior research are implicitly addressed by the trial design (e.g., randomized, placebo-controlled), though not explicitly discussed in the introduction.
“Several small-molecule drugs (e.g., nirmatrelvir and ensitrelvir ) targeting the SARS-CoV-2 3-chymotrypsin–like cysteine protease enzyme (3CLpro, also known as main protease [Mpro]) are available.”
“In vitro simnotrelvir showed antiviral activity with a half maximal effective concentration of 43 nmol per liter against the SARS-CoV-2 omicron variant B.1.1.529.1”
“Simnotrelvir (SIM0417) is an oral small-molecule antiviral agent that also targets the SARS-CoV-2 3CLpro.”
“We conducted a phase 2–3, double-blind, randomized, placebo-controlled trial to investigate the efficacy and safety of simnotrelvir plus ritonavir in the treatment of adult patients with mild-to-moderate Covid-19.”
Randomization was performed via a centralized interactive-response technology system with 1:1 allocation, stratified by region, age, and vaccination status. Blinding of patients and investigators is described, and the placebo was visually identical. A power analysis was conducted, and inclusion/exclusion criteria were prespecified. The modified intention-to-treat-1 population was defined as the main analysis population. Outlier handling is addressed through the definition of analysis populations and missing data handling (referenced to protocol). Controls are inherent in the placebo arm. Independent replication is not applicable for a single pivotal trial.
“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system”
“Patients and investigators were unaware of the randomization assignments.”
“we calculated that a sample of 960 patients, with 949 of these patients having sustained resolution of symptoms, would provide at least 90% power to detect a 24-hour difference in the median time to sustained resolution of symptoms”
“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system, to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”
“Patients and investigators were unaware of the randomization assignments.”
“Assuming that only 80% of 1200 patients enrolled in the trial would be included in the primary analysis, we calculated that a sample of 960 patients, with 949 of these patients having sustained resolution of symptoms, would provide at least 90% power to detect a 24-hour difference in the median time to sustained resolution of symptoms between the simnotrelvir group and the placebo group at a two-sided significance level of 0.05.”
Sex is reported for the full analysis population (58.1% male in simnotrelvir group, 60.1% in placebo). Age is reported as median (IQR) of 35 years. Health status is captured through risk factors and disease severity. Demographics are adequately reported for a clinical trial. Species/strain and housing conditions are not applicable.
“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”
“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”
“At least one risk factor | 302 (52.7) | 307 (54.2) | 609 (53.5)”
“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”
“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”
“Overall, the trial recruited a fully vaccinated and relatively young population, with approximately half the patients (609 [53.5%]) having at least one risk factor for severe Covid-19 (Table S6).”
The trial was approved by the ethics committee at each site, and written informed consent was obtained from all patients. The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines. This satisfies all applicable criteria for a human interventional trial.
“The trial was approved by the ethics committee at each site.”
“Written informed consent was obtained from all patients.”
“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”
“The trial was approved by the ethics committee at each site.”
“Written informed consent was obtained from all patients.”
“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”
The investigational product is clearly identified: simnotrelvir 750 mg plus ritonavir 100 mg, with formulation details (two tablets, 375 mg per tablet). The placebo is described as visually identical. Statistical software (SAS 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.
“to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”
“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”
“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system, to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”
“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”
The primary analysis used a Peto-Prentice test with stratification, and p-values are reported exactly (P=0.006). Effect sizes are reported with 95% CIs. Statistical software is identified. Data presentation includes Kaplan-Meier curves and per-group n. Assumptions are handled by design (stratified test, mixed models for viral load). Mathematical plausibility checks were not performed due to lack of recomputable statistics.
“P=0.006 by Peto–Prentice test”
“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”
“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”
“P=0.006 by Peto–Prentice test”
“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”
“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”
The paper mentions a 'Data Sharing Statement' but the actual content is not provided in the text. No repository deposit or accession numbers are mentioned. Code sharing is not applicable as no custom code is described. The data availability statement is vague, lacking a concrete access route.
“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”
“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”
Trial registration number is provided (NCT05506176). Methods are comprehensive. Limitations are explicitly discussed (e.g., young population, potential unblinding due to ritonavir taste). Conclusions are appropriately cautious. Funding and COI are stated. Reporting guideline adherence is implied by NEJM standards but not explicitly mentioned.
“ClinicalTrials.gov number, NCT05506176”
“the placebo contained only excipients; therefore, unblinding may have occurred in some patients, given the unique taste of ritonavir.”
“Supported by Jiangsu Simcere Pharmaceutical.”
“ClinicalTrials.gov number, NCT05506176”
“Third, the recruited population was relatively young. The efficacy and safety among older patients still warrants investigations in future research.”
“Supported by Jiangsu Simcere Pharmaceutical.”
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 19 references by DOI: 3 verified — 16 no DOI (shown, not verified).
- NO DOICOVID-19 dashboardNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIImprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolutionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjectsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEfficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAssessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatmentNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA multiple testing procedure for clinical trialsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICOVID-19 and the heartNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHealth-related quality of life of the adult COVID-19 patients following one-month illness experience since diagnosis: findings of a cross-sectional study in BangladeshNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHealth outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or deathNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAnalyst and investor call to discuss the first COVID-19 comprehensive approach: Pfizer-BioNTech vaccine and Pfizer’s novel oral antiviral treatment candidateNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIShionogi announces achievement of the primary endpoint for ensitrelvir fumaric acid (S-217622) in the phase 3 part of the phase 2/3 clinical trial in AsiaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIMolnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINirmatrelvir use and severe Covid-19 outcomes during the omicron surgeNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIReal-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIVV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
1 data/code link checked; 1 live.
- datahttp://clinicaltrials.gov/show/NCT05506176LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly typo, consistency.
- MINORtypoAbstract, Methods“Two efficacy interim analysis were planned”→ Change to 'Two efficacy interim analyses were planned'Subject-verb agreement error.
- MINORconsistencyMethods, Statistical Analysis“Two efficacy interim analysis were planned for when 45% and 70% of the total predicted instances of resolution had occurred”→ Ensure consistent use of 'analysis' vs 'analyses' throughout.Inconsistent pluralization.
- MINORtypoAbstract, Methods“Two efficacy interim analysis were planned”→ Two efficacy interim analyses were plannedSubject-verb agreement error.
- MINORconsistencyResults, paragraph 1“After randomization, 1139 patients received trial drug or placebo and were included in the full analysis population.”→ Ensure consistency with the CONSORT flow diagram.The number 1139 is consistent with Table 1, but the flow diagram is not shown in the text.
The published work is robust and trustworthy, with no major rigor gaps. An informed reader should weigh the vague data sharing statement and the lack of explicit CONSORT adherence as minor transparency limitations, but these do not undermine the validity of the findings. No erratum or re-analysis is warranted based on the evidence reviewed.
- 1.HIGHdata codeExpand the Data Sharing Statement in the main text to specify the mechanism for accessing de-identified patient data (e.g., via a data access committee or a repository like Vivli) and the conditions for access.The current statement is vague and does not provide a concrete access route, which is a transparency gap for a data-driven clinical trial.
- 2.HIGHreportingExplicitly state adherence to CONSORT reporting guidelines in the Methods or a separate section, and consider submitting the CONSORT checklist as supplementary material.Explicit guideline adherence enhances transparency and is expected for randomized trials.
- 3.MEDIUMreportingClarify the handling of missing data in the statistical analysis section, as it is only referenced to the protocol.Readers need to know how missing data were handled to assess the robustness of the primary analysis.
- 4.MEDIUMreportingProvide a CONSORT flow diagram in the main text to enhance transparency of patient disposition.A flow diagram clarifies the number of patients excluded at each stage and supports the reported analysis populations.
- 5.MEDIUMreportingInclude a statement on the availability of the full trial protocol and statistical analysis plan.Providing access to the protocol and SAP supports reproducibility and transparency.
- 6.MEDIUMreportingProvide more detail on the randomization implementation (e.g., block sizes, allocation concealment) in the main text.Additional detail on randomization strengthens the description of the trial design.
- 7.LOWcopyeditFix the subject-verb agreement error in the Abstract and Methods: change 'Two efficacy interim analysis were planned' to 'Two efficacy interim analyses were planned'.Correct grammar improves professionalism and readability.
- 8.LOWcopyeditEnsure consistent use of 'analysis' vs 'analyses' throughout the manuscript.Consistency in terminology avoids confusion.
- 9.LOWdata codeConsider depositing de-identified aggregate data or statistical analysis code in a public repository to enhance transparency.Public data/code deposit increases reproducibility and reader trust.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.